Infant Bacterial Therapeutics (IBT) öppnar en sista kohort vilket påskyndar rekryteringen av patienter
March 22, 2023 05:31 ET
|
Infant Bacterial Therapeutics AB
IBT är glada att kunna meddela dagens öppning av den ytterligare kohorten, efter att ha inkluderat 1400 för tidigt födda barn av det totala rekryteringsmålet på 2158. Fram tills nu, och i enlighet men...
Infant Bacterial Therapeutics’ (IBT) opening of a final infant cohort will accelerate patient recruitment
March 22, 2023 05:31 ET
|
Infant Bacterial Therapeutics AB
IBT is pleased to announce today's opening of the additional cohort, having included 1,400 premature infants of the total 2,158 recruitment target. Up until now, and per the protocol agreed with...
Infant Bacterial Therapeutics AB (publ) Bokslutskommuniké 1 januari – 31 december 2022
February 10, 2023 02:00 ET
|
Infant Bacterial Therapeutics AB
VD kommenterar Under de sista tre månaderna av 2022 var rekryteringen av prematura spädbarn till vår omfattande fas 3 studie betydligt bättre än vad den var under motsvarande period de föregående...
Infant Bacterial Therapeutics publishes Annual Report for 2021 in XHTML format
January 27, 2023 08:55 ET
|
Infant Bacterial Therapeutics AB
On March 31 2022 IBT published the 2021 annual report in the format of a PDF file. Today, IBT publish the same report in the XHTML format. The content of the report has not been changed. see...
Infant Bacterial Therapeutics’ (IBT) publishes clinical findings in the British Journal of Gastroenterology on the convincing association of clinical events to the feeding primary endpoint of the ‘Connection Study’
January 24, 2023 11:43 ET
|
Infant Bacterial Therapeutics AB
The ‘Connection Study’ on the pharmaceutical grade probiotic IBP-9414 has two independent primary endpoints- the incidence of Necrotizing Enterocolitis (NEC) and the time to a strict definition of...
Infant Bacterial Therapeutics AB (publ) (IBT), delårsrapport 1 juli – 30 september 2022
November 10, 2022 02:00 ET
|
Infant Bacterial Therapeutics AB
VD kommenterar Vårt utvecklingsprojekt IBP-9414 i klinisk fas III fortskrider väl, och som jag tidigare nämnt arbetar vi med flera aktiviteter för att påskynda genomförandet av vår studie. Det är...
Infant Bacterial Therapeutics AB (publ) (IBT), Interim Management Statement, July 1 – September 30, 2022
November 10, 2022 02:00 ET
|
Infant Bacterial Therapeutics AB
Message from the CEO Our IBP-9414 clinical phase III development project is progressing well, and as previously mentioned, we are pursuing several initiatives to accelerate study execution. It is...